BD Biosciences Launches New Cell Analyzer to Streamline Research Workflow

SAN JOSE, Calif., May 20, 2011 /PRNewswire/ -- BD Biosciences, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), launched today the BD FACSVerse™ Flow Cytometer, a flexible, reliable and scalable system that can analyze up to 10 parameters and support a wide range of research applications.  

“We engineered cutting-edge innovation into the BD FACSVerse System from the ground up, with three foundations in mind,” said James Glasscock, President of Cell Analysis, BD Biosciences.  “First, we wanted to provide researchers with a single system that could handle routine applications along with complex multi-color experiments with precision and reproducibility.  Second, we sought to streamline workflow and make the system easy to use with built-in intelligence. Lastly, we wanted to help protect our customers’ investment by giving them an upgrade path from 6 parameters up to 10 parameters as well as multiple optional capabilities that will allow them to meet the future demands of their research.”

With the new BD FACSuite™ Software System for the BD FACSVerse Flow Cytometer, users can now automate routine tasks, such as instrument startup, setup, sample acquisition, and data analysis, and complete others with minimal clicks  The software package's modular architecture enables users to multitask, performing data analysis while the system is acquiring data. According to Glasscock, the software introduces a powerful new paradigm that eliminates the need for daily spill over correction, which is essential for today's multicolor analysis.  BD FACSuite Software enables assays and experiments to be exported to other BD FACSVerse Systems around the globe, minimizing commonly encountered system and user-related variances.

The BD FACSVerse Flow Cytometer has built-in intelligence that is intended to reduce errors, increase efficiency, automate processes and minimize user interaction. Some examples include:

• Vacuum-based fluidic subsystem that allows exceptional flexibility in sample introduction;
• New setup and QC concepts that eliminate the need for daily compensation for standard fluorochromes; and,
• Intelligence and innovation that are built into components across the system that streamline many operations and prevent errors

To support a wide range of applications, the system provides optional predefined BD research assays for apoptosis, cell cycle, cell proliferation, and cytokine detection, which are matched with BD reagent kits for reproducible results. The system also facilitates the development of user-defined experiments.  Researchers can convert their experiments to reusable assays that include relevant settings, acquisition and analysis worksheets, and gating strategies.  They can also establish report parameters to reduce data variability between users and laboratories for the same application.

The BD FACSVerse Flow Cytometer is available in 4-color, 6-color and 8-color configurations with forward-scatter and side-scatter support for up to 10 total parameters. The 4- and 6-color systems can be expanded with a field upgrade. The system has a compact footprint that enables it to fit easily on standard laboratory bench tops.  

For more information on the BD FACSVerse Flow Cytometer, please visit: http://bdbiosciences.com/go/verse

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

Contact: Jeff Ezell
BD Public Relations
(201) 847-5533
[email protected]

SOURCE BD-Becton Dickinson